• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BRCA1/2 基因检测结果向雇主自发披露:一项法国前瞻性研究。

Spontaneous disclosure of BRCA1/2 genetic test results to employers: a French prospective study.

机构信息

Institut Paoli-Calmettes, Marseille, France.

出版信息

Eur J Hum Genet. 2012 Sep;20(9):981-3. doi: 10.1038/ejhg.2012.37. Epub 2012 Feb 29.

DOI:10.1038/ejhg.2012.37
PMID:22378286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3421122/
Abstract

The aim of this study was to examine the patterns of disclosure of BRCA1/2 genetic test results to employers by unaffected carriers. In a national prospective cohort study on unaffected BRCA1/2 mutation carriers, disclosure to employers was assessed prospectively, using self-administered questionnaires, up to 2 years after their test results were delivered by cancer geneticists. Kaplan-Meier curves and Cox-regression analysis were used to assess the factors associated with time to disclosure to the employer. Mean age of the 146 women BRCA1/2 carriers who were employed when their test results were delivered was 37.1 years (range: 19-57). At the end of the second year of follow-up, 47 of them (32.2%) had disclosed their results to their employers; median time to disclosure was 6 months. Reasons spontaneously expressed were first to inform the employer that medical surveillance/surgery was necessary for cancer risk management although these carriers did not actually have cancer. After multivariate adjustment on age, women with a lower educational level (HRadj=2.00, P=0.026) and those who had undergone prophylactic surgery during the 2 years of follow-up (HRadj=2.18, P=0.019) had disclosed their BRCA status to their employers earlier and more frequently. One-third of the female carriers not affected by breast/ovarian cancer disclosed their BRCA1/2 genetic test results spontaneously to their employers, mainly to inform them that they were disease-free but required medical surveillance or a surgical intervention to reduce the risk of cancer.

摘要

本研究旨在探讨未受影响的 BRCA1/2 基因突变携带者向雇主披露基因检测结果的模式。在一项针对未受影响的 BRCA1/2 突变携带者的全国前瞻性队列研究中,使用自我管理问卷前瞻性评估了向雇主披露的情况,直至癌症遗传学家提供检测结果后 2 年。使用 Kaplan-Meier 曲线和 Cox 回归分析评估了与向雇主披露时间相关的因素。在提供检测结果时就业的 146 名 BRCA1/2 携带者的平均年龄为 37.1 岁(范围:19-57)。在随访的第二年结束时,其中 47 人(32.2%)已向雇主披露了结果;中位披露时间为 6 个月。自发表达的原因首先是通知雇主,为了进行癌症风险管理,医学监测/手术是必要的,尽管这些携带者实际上没有癌症。在对年龄进行多变量调整后,教育程度较低的女性(HRadj=2.00,P=0.026)和在随访的 2 年内接受预防性手术的女性(HRadj=2.18,P=0.019)更早且更频繁地向雇主披露了 BRCA 状态。三分之一未受乳腺癌/卵巢癌影响的女性携带者自发向雇主披露了 BRCA1/2 基因检测结果,主要是告知他们没有患病,但需要医学监测或手术干预以降低癌症风险。

相似文献

1
Spontaneous disclosure of BRCA1/2 genetic test results to employers: a French prospective study.BRCA1/2 基因检测结果向雇主自发披露:一项法国前瞻性研究。
Eur J Hum Genet. 2012 Sep;20(9):981-3. doi: 10.1038/ejhg.2012.37. Epub 2012 Feb 29.
2
Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?哪些因素可预测BRCA1/2检测结果披露后心理咨询的提议及接受情况?
Psychooncology. 2014 Apr;23(4):420-7. doi: 10.1002/pon.3435. Epub 2013 Oct 11.
3
Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics.BRCA1/2 携带者预防性手术的时间取决于心理和其他特征。
Genet Med. 2010 Dec;12(12):801-7. doi: 10.1097/GIM.0b013e3181f48d1c.
4
Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral.家族转诊时未受影响的 BRCA1/2 基因突变携带者行降低风险手术可提高生存率。
Breast Cancer Res Treat. 2013 Dec;142(3):611-8. doi: 10.1007/s10549-013-2765-x. Epub 2013 Nov 20.
5
Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec.BRCA1/2 突变阳性家族中无携带者的乳腺癌和卵巢癌筛查:来自法国和魁北克队列的 2 年随访。
Eur J Hum Genet. 2011 May;19(5):494-9. doi: 10.1038/ejhg.2010.227. Epub 2011 Jan 19.
6
An investigation of the disclosure process and support needs of BRCA1 and BRCA2 carriers.一项关于BRCA1和BRCA2基因携带者信息披露过程及支持需求的调查。
Am J Med Genet A. 2004 Mar 15;125A(3):267-72. doi: 10.1002/ajmg.a.20485.
7
Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.X染色体失活偏倚与乳腺癌和卵巢癌状态:BRCA1的X连锁修饰因子的证据
J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.
8
Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.BRCA1/2 基因突变预测性基因检测后 5 年未受影响女性的癌症风险管理策略和认知。
Eur J Hum Genet. 2011 May;19(5):500-6. doi: 10.1038/ejhg.2010.241. Epub 2011 Jan 26.
9
Cigarette smoking in women after BRCA1/2 genetic test disclosure: a 5-year follow-up study of the GENEPSO PS cohort.BRCA1/2 基因检测结果披露后女性的吸烟行为:GENEPSO PS 队列的 5 年随访研究。
Genet Med. 2015 Feb;17(2):117-24. doi: 10.1038/gim.2014.82. Epub 2014 Jul 10.
10
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.在一组前瞻性队列中,对未受影响的BRCA1和BRCA2基因突变携带者进行双侧预防性卵巢切除术和双侧预防性乳房切除术。
Clin Breast Cancer. 2007 Dec;7(11):875-82. doi: 10.3816/CBC.2007.n.053.

引用本文的文献

1
Validation of a scale for assessing attitudes towards outcomes of genetic cancer testing among primary care providers and breast specialists.评估初级保健提供者和乳腺专科医生对遗传性癌症检测结果态度的量表的验证
PLoS One. 2017 Jun 1;12(6):e0178447. doi: 10.1371/journal.pone.0178447. eCollection 2017.
2
Concerns about Genetic Testing for Schizophrenia among Young Adults at Clinical High Risk for Psychosis.对处于精神病临床高危状态的年轻成年人进行精神分裂症基因检测的担忧。
AJOB Empir Bioeth. 2016;7(3):193-198. doi: 10.1080/23294515.2015.1084553. Epub 2015 Nov 16.
3
Disclosure of research results: a randomized study on GENEPSO-PS cohort participants.研究结果披露:一项针对GENEPSO-PS队列参与者的随机研究。
Health Expect. 2016 Oct;19(5):1023-35. doi: 10.1111/hex.12390. Epub 2015 Jul 23.
4
"Maybe they have found something new" participants' views on returning cohort psychosocial survey results.“也许他们发现了新东西”:参与者对返还队列心理社会调查结果的看法
Health Expect. 2015 Dec;18(6):2425-36. doi: 10.1111/hex.12211. Epub 2014 May 30.

本文引用的文献

1
Social and ethical implications of BRCA testing.BRCA 检测的社会伦理影响。
Ann Oncol. 2011 Jan;22 Suppl 1:i60-6. doi: 10.1093/annonc/mdq668.
2
Assessing disease disclosure in adults with cystic fibrosis: the Adult Data for Understanding Lifestyle and Transitions (ADULT) survey Disclosure of disease in adults with cystic fibrosis.评估成人囊性纤维化患者的疾病披露情况:成人数据理解生活方式和转变(ADULT)调查 成人囊性纤维化患者的疾病披露情况。
BMC Pulm Med. 2010 Sep 10;10:46. doi: 10.1186/1471-2466-10-46.
3
"Should I tell my employer and coworkers I have arthritis?" A longitudinal examination of self-disclosure in the work place.“我应该告诉雇主和同事我患有关节炎吗?”工作场所自我披露情况的纵向研究。
Arthritis Rheum. 2009 Dec 15;61(12):1753-61. doi: 10.1002/art.24889.
4
Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey.亨廷顿舞蹈症高危人群对基因歧视的认知:一项横断面调查
BMJ. 2009 Jun 9;338:b2175. doi: 10.1136/bmj.b2175.
5
Genetic discrimination in Huntington's disease.亨廷顿舞蹈症中的基因歧视
BMJ. 2009 Jun 9;338:b1281. doi: 10.1136/bmj.b1281.
6
Verification of consumers' experiences and perceptions of genetic discrimination and its impact on utilization of genetic testing.对消费者关于基因歧视的经历和认知及其对基因检测利用的影响进行验证。
Genet Med. 2009 Mar;11(3):193-201. doi: 10.1097/GIM.0b013e318194ee75.
7
Keeping pace with the times--the Genetic Information Nondiscrimination Act of 2008.与时俱进——2008年《遗传信息非歧视法案》
N Engl J Med. 2008 Jun 19;358(25):2661-3. doi: 10.1056/NEJMp0803964.
8
Perceptions of discrimination among persons who have undergone predictive testing for Huntington's disease.对接受亨廷顿舞蹈症预测性检测者的歧视认知
Am J Med Genet B Neuropsychiatr Genet. 2008 Apr 5;147(3):320-5. doi: 10.1002/ajmg.b.30600.
9
Essentially yours: the protection of human genetic information in Australia.
Genewatch. 2006 Jan-Feb;19(1):9-12.
10
Genetic information and testing in insurance and employment: technical, social and ethical issues.保险与就业中的遗传信息及检测:技术、社会与伦理问题
Eur J Hum Genet. 2003 Dec;11 Suppl 2:S123-42. doi: 10.1038/sj.ejhg.5201117.